NCT04976036: Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Patients
- State
- Under way
- Phase
- Phase 2
- People
- 48 planned
- Started
- 5 May 2022
- Primary completion
- Dec 2026
- Arms
- Nintedanib
- Results
- None posted
- 26 Jul 2021: Trial registered
- 5 May 2022: Trial started